Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | UBE2M | P61081 | 1/20 | 0.38 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30191057 | 1.00 | ALDH1A1 (0.48) | ALDH1A1USP2HTTTSHRSMN1; SMN2 | |
| SCHEMBL13304238 | 1.00 | ALDH1A1 (0.48) | ALDH1A1USP2HTTTSHRSMN1; SMN2 | |
| SCHEMBL12176470 | 1.00 | ALDH1A1 (0.48) | ALDH1A1USP2HTTTSHRSMN1; SMN2 | |
| SCHEMBL18609857 | 1.00 | ALDH1A1 (0.48) | ALDH1A1USP2HTTTSHRSMN1; SMN2 | |
| SCHEMBL29726762 | 1.00 | ALDH1A1 (0.48) | ALDH1A1USP2HTTTSHRSMN1; SMN2 | |
| SCHEMBL12176271 | 0.99 | ALDH1A1 (0.47) | ALDH1A1USP2HTTTSHRSMN1; SMN2 | |
| SCHEMBL13060084 | 0.98 | ALDH1A1 (0.46) | ALDH1A1USP2HTTTSHRSMN1; SMN2 | |
| SCHEMBL12176368 | 0.96 | ALDH1A1 (0.43) | ALDH1A1USP2HTTTSHRSMN1; SMN2 | |
| SCHEMBL18801841 | 0.94 | EPHX2 (0.43) | ALDH1A1USP2HTTTSHRSMN1; SMN2 | |
| SCHEMBL12176114 | 0.94 | EPHX2 (0.43) | ALDH1A1USP2HTTTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845729-B2 | Processes and intermediates in the preparation of C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-11779576-B2 | Method of treating C3 glomerulopathy | CHEMOCENTRYX, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779576-B2 | Method of treating C3 glomerulopathy | CHEMOCENTRYX, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230102258-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20230008966-A1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20230008966-A1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2023-01-12 | — | — | US | disclosed |
| EP-3682879-B1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2022-08-03 | — | — | EP | disclosed |
| WO-2022140258-A1 | TREATMENT OF C3 GLOMERULOPATHY USING A C5A INHIBITOR | CHEMOCENTRYX, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220125775-A1 | METHODS OF TREATING HIDRADENITIS SUPPURATIVA | CHEMOCENTRYX, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20220047592-A1 | METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS | CHEMOCENTRYX, INC. | 2022-02-17 | — | — | US | disclosed |
| US-8906938-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20130172347-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2013-07-04 | — | — | US | disclosed |
| US-20130172347-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2013-07-04 | — | — | US | disclosed |
| US-8445515-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445515-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110275639-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275639-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| EP-2381778-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20100311753-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311753-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275639-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | ALDH1A1 2966/4885USP2 3279/4885HTT 3069/4885 |
| US-11779576-B2 | Method of treating C3 glomerulopathy | C3AR1, C5, C5AR1 | ALDH1A1 3270/4885USP2 2253/4885HTT 3219/4885 |
| US-11845729-B2 | Processes and intermediates in the preparation of C5aR antagonists | C5AR1, C5AR2, C3AR1 | ALDH1A1 3319/4885USP2 2984/4885HTT 3978/4885 |
| US-20230102258-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | ALDH1A1 2966/4885USP2 3279/4885HTT 3069/4885 |
| US-20100311753-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | ALDH1A1 2966/4885USP2 3279/4885HTT 3069/4885 |
| US-20230008966-A1 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | ALDH1A1 3319/4885USP2 2984/4885HTT 3978/4885 |
| US-20130172347-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | ALDH1A1 2966/4885USP2 3279/4885HTT 3069/4885 |
| US-20220047592-A1 | METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS | C3AR1, C5, C5AR1 | ALDH1A1 1801/4885USP2 1997/4885HTT 3221/4885 |
| US-20220125775-A1 | METHODS OF TREATING HIDRADENITIS SUPPURATIVA | MMP8, MPO, ELANE | ALDH1A1 270/4885USP2 3519/4885HTT 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.